Cargando…

Serum Sclerostin But Not DKK-1 Correlated with Central Arterial Stiffness in End Stage Renal Disease Patients

Sclerostin and dickkopf-1 (DKK1) played a role in the development of cardiovascular diseases and arterial stiffness in chronic kidney disease (CKD) patients but with controversial results of patients in end-stage renal disease (ESRD) including hemodialysis (HD) and peritoneal dialysis (PD). This stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Chun-Feng, Hou, Jia-Sian, Wang, Chih-Hsien, Lin, Yu-Li, Lai, Yu-Hsien, Kuo, Chiu-Huang, Liou, Hung-Hsiang, Tsai, Jen-Pi, Hsu, Bang-Gee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068530/
https://www.ncbi.nlm.nih.gov/pubmed/32075016
http://dx.doi.org/10.3390/ijerph17041230
_version_ 1783505601118076928
author Wu, Chun-Feng
Hou, Jia-Sian
Wang, Chih-Hsien
Lin, Yu-Li
Lai, Yu-Hsien
Kuo, Chiu-Huang
Liou, Hung-Hsiang
Tsai, Jen-Pi
Hsu, Bang-Gee
author_facet Wu, Chun-Feng
Hou, Jia-Sian
Wang, Chih-Hsien
Lin, Yu-Li
Lai, Yu-Hsien
Kuo, Chiu-Huang
Liou, Hung-Hsiang
Tsai, Jen-Pi
Hsu, Bang-Gee
author_sort Wu, Chun-Feng
collection PubMed
description Sclerostin and dickkopf-1 (DKK1) played a role in the development of cardiovascular diseases and arterial stiffness in chronic kidney disease (CKD) patients but with controversial results of patients in end-stage renal disease (ESRD) including hemodialysis (HD) and peritoneal dialysis (PD). This study aimed to examine the association between the mode of dialysis or the values of sclerostin or DKK1 and carotid-femoral pulse wave velocity (cfPWV) in ESRD patients. There were 122 HD and 72 PD patients enrolled in this study. By a validated tonometry system, cfPWV was measured and then segregated patients into values of >10 m/s as the high central arterial stiffness (AS) group and values ≤ 10 m/s as the control group. Serum levels of sclerostin and DKK1 were measured using a commercial enzyme-linked immunosorbent assay kit. Possible risk factors for the development of AS were analyzed by logistic regression analysis. There were 21 (29.2%) of PD and 53 (43.4%) of HD in the high AS group. Compared to patients in the control group, those in the high AS group were older, had more comorbidities, had higher systolic blood pressure, and had higher serum levels of fasting glucose, C-reactive protein, and sclerostin. Levels of sclerostin (adjusted OR 1.012, 95% CI. 1.006–1.017, p = 0.0001) was found to be an independent predictor of high AS in ESRD patients by multivariate logistic regression analysis. Furthermore, receiver operating characteristic curve analysis showed the optimal cut-off values of sclerostin for predicting AS was 208.64 pmol/L (Area under the curve 0.673, 95% CI: 0.603–0.739, p < 0.001). This study showed that serum levels of sclerostin, but not DKK1 or mode of dialysis, to be a predictor for high central AS in ESRD patients.
format Online
Article
Text
id pubmed-7068530
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70685302020-03-19 Serum Sclerostin But Not DKK-1 Correlated with Central Arterial Stiffness in End Stage Renal Disease Patients Wu, Chun-Feng Hou, Jia-Sian Wang, Chih-Hsien Lin, Yu-Li Lai, Yu-Hsien Kuo, Chiu-Huang Liou, Hung-Hsiang Tsai, Jen-Pi Hsu, Bang-Gee Int J Environ Res Public Health Article Sclerostin and dickkopf-1 (DKK1) played a role in the development of cardiovascular diseases and arterial stiffness in chronic kidney disease (CKD) patients but with controversial results of patients in end-stage renal disease (ESRD) including hemodialysis (HD) and peritoneal dialysis (PD). This study aimed to examine the association between the mode of dialysis or the values of sclerostin or DKK1 and carotid-femoral pulse wave velocity (cfPWV) in ESRD patients. There were 122 HD and 72 PD patients enrolled in this study. By a validated tonometry system, cfPWV was measured and then segregated patients into values of >10 m/s as the high central arterial stiffness (AS) group and values ≤ 10 m/s as the control group. Serum levels of sclerostin and DKK1 were measured using a commercial enzyme-linked immunosorbent assay kit. Possible risk factors for the development of AS were analyzed by logistic regression analysis. There were 21 (29.2%) of PD and 53 (43.4%) of HD in the high AS group. Compared to patients in the control group, those in the high AS group were older, had more comorbidities, had higher systolic blood pressure, and had higher serum levels of fasting glucose, C-reactive protein, and sclerostin. Levels of sclerostin (adjusted OR 1.012, 95% CI. 1.006–1.017, p = 0.0001) was found to be an independent predictor of high AS in ESRD patients by multivariate logistic regression analysis. Furthermore, receiver operating characteristic curve analysis showed the optimal cut-off values of sclerostin for predicting AS was 208.64 pmol/L (Area under the curve 0.673, 95% CI: 0.603–0.739, p < 0.001). This study showed that serum levels of sclerostin, but not DKK1 or mode of dialysis, to be a predictor for high central AS in ESRD patients. MDPI 2020-02-14 2020-02 /pmc/articles/PMC7068530/ /pubmed/32075016 http://dx.doi.org/10.3390/ijerph17041230 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wu, Chun-Feng
Hou, Jia-Sian
Wang, Chih-Hsien
Lin, Yu-Li
Lai, Yu-Hsien
Kuo, Chiu-Huang
Liou, Hung-Hsiang
Tsai, Jen-Pi
Hsu, Bang-Gee
Serum Sclerostin But Not DKK-1 Correlated with Central Arterial Stiffness in End Stage Renal Disease Patients
title Serum Sclerostin But Not DKK-1 Correlated with Central Arterial Stiffness in End Stage Renal Disease Patients
title_full Serum Sclerostin But Not DKK-1 Correlated with Central Arterial Stiffness in End Stage Renal Disease Patients
title_fullStr Serum Sclerostin But Not DKK-1 Correlated with Central Arterial Stiffness in End Stage Renal Disease Patients
title_full_unstemmed Serum Sclerostin But Not DKK-1 Correlated with Central Arterial Stiffness in End Stage Renal Disease Patients
title_short Serum Sclerostin But Not DKK-1 Correlated with Central Arterial Stiffness in End Stage Renal Disease Patients
title_sort serum sclerostin but not dkk-1 correlated with central arterial stiffness in end stage renal disease patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068530/
https://www.ncbi.nlm.nih.gov/pubmed/32075016
http://dx.doi.org/10.3390/ijerph17041230
work_keys_str_mv AT wuchunfeng serumsclerostinbutnotdkk1correlatedwithcentralarterialstiffnessinendstagerenaldiseasepatients
AT houjiasian serumsclerostinbutnotdkk1correlatedwithcentralarterialstiffnessinendstagerenaldiseasepatients
AT wangchihhsien serumsclerostinbutnotdkk1correlatedwithcentralarterialstiffnessinendstagerenaldiseasepatients
AT linyuli serumsclerostinbutnotdkk1correlatedwithcentralarterialstiffnessinendstagerenaldiseasepatients
AT laiyuhsien serumsclerostinbutnotdkk1correlatedwithcentralarterialstiffnessinendstagerenaldiseasepatients
AT kuochiuhuang serumsclerostinbutnotdkk1correlatedwithcentralarterialstiffnessinendstagerenaldiseasepatients
AT liouhunghsiang serumsclerostinbutnotdkk1correlatedwithcentralarterialstiffnessinendstagerenaldiseasepatients
AT tsaijenpi serumsclerostinbutnotdkk1correlatedwithcentralarterialstiffnessinendstagerenaldiseasepatients
AT hsubanggee serumsclerostinbutnotdkk1correlatedwithcentralarterialstiffnessinendstagerenaldiseasepatients